85 WELLS AVENUE, NEWTON, MA
Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
Karyopharm Implements 2026 Leadership Cash Retention Program
Karyopharm Therapeutics Inc. Approves 2022 Equity Incentive Plan Amendment
Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
Annual Report to Security Holders
Other Events
Investor Presentation
News, Material Contracts
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Tender Offer Statement by Issuer